Anti-MET (HGF receptor, HGFR, Hepatocyte Growth Factor Receptor, Scatter Factor Receptor, SF Recepto

MET/HGFR is a receptor for hepatocyte growth factor, with tyrosine-protein kinase activity. The MET/HGFR Type I membrane protein contains 1 Sema domain and consists of a heterodimer formed of an alpha chain (50kD) and a beta chain (145kD) which are disulfide linked. In the fully processed c-Met product, the alpha subunit is extracellular, and the beta subunit has extracellular, transmembrane, and tyrosine kinase domains as well as sites of tyrosine phosphorylation. Two isoforms for the protein have been described. Activation of MET after rearrangement with the TPR gene produces an oncogenic protein. MET is overexpressed in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis. Defects in MET are a cause of hereditary papillary renal carcinoma (HPRC), also known as papillary renal cell carcinoma 2 (RCCP2). HPRC is a form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors. The pattern of inheritance is consistent with autosomal dominant transmission with reduced penetrance. Applications: Suitable for use in ELISA, Immunohistochemistry and Western Blot. Other applications not tested. Recommended Dilutions: ELISA: 1:1000, Immunohistochemistry: 1:50-1:100, Western Blot: 1:100-1:500, Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.